Eczema is often assumed to be a childhood disease; however, the skin condition also affects adults and its prevalence is continually increasing. About half as many adults are affected by eczema than children, but it can negatively influence their quality of life.
Eczema is often assumed to be a childhood disease; however, the skin condition also affects adults and its prevalence is continually increasing.
Eczema, or atopic dermatitis, involves red and dry patches of skin that often causes itchiness. According to Jonathan I. Silverberg, MD, PhD, MPH, FAAD, an assistant professor at Northwestern University Feinberg School of Medicine and director of the Northwestern Medicine Multidisciplinary Eczema Center in Chicago, in recent estimates, about half as many adults are affected by eczema than children, but it can negatively influence their quality of life.
“Adult eczema patients may have dealt with their symptoms for their entire lives, which can be draining, or they may experience symptoms for the first time as adults, which can be a difficult adjustment,” explained Silverberg in a press release. “Either way, this condition can take a real toll on them… People who aren’t familiar with the disease might say ‘It’s just eczema.’ But for many patients, it’s not ‘just eczema.’ It can be debilitating.”
Living with eczema often comes with difficulties in everyday routine tasks, could negatively impact work attendance and performance, cause sleeping issues, and lead to mental health issues. Silverberg also describes how certain social situations may be more challenging for those with visible eczema because of the negative stigma and inaccurate assumptions that others make about the disease, such as it being contagious or linked to poor hygiene.
“Fortunately for patients, eczema treatment can help alleviate the negative effects of this disease and improve their physical and mental well-being,” he reassures.
Atopic dermatitis is most commonly treated with moisturizers, topical steroids, phototherapy, or systemic medications. In addition, the FDA has recently approved of an anti-inflammatory topical medication for mild to moderate forms of the disease, and an injectable systemic drug for moderate to severe disease types.
“This is an exciting time that offers a lot of hope and promise for people with eczema, both children and adults,” Silverberg states in reference to the new treatments in the development pipeline. “If you’re struggling with this disease, there are treatment options out there for you, and a board-certified dermatologist can help you find the eczema management plan that works best for you and improve your quality of life.”
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
Neoadjuvant Chemotherapy Becomes Leading Initial Treatment for Advanced Epithelial Ovarian Cancer
October 22nd 2024By 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery became the most common initial treatment for patients with advanced epithelial ovarian cancer, overtaking primary cytoreductive surgery.
Read More